Theratechnologies Inc. (THTX)
1.57
-0.01 (-0.63%)
At close: Mar 24, 2025, 3:59 PM
1.60
1.82%
After-hours: Mar 24, 2025, 07:59 PM EDT
-0.63% (1D)
| Bid | 1.56 |
| Market Cap | 72.19M |
| Revenue (ttm) | 76.64M |
| Net Income (ttm) | -7.41M |
| EPS (ttm) | -0.17 |
| PE Ratio (ttm) | -9.24 |
| Forward PE | 28.93 |
| Analyst | n/a |
| Ask | 1.59 |
| Volume | 229,034 |
| Avg. Volume (20D) | 114,051 |
| Open | 1.58 |
| Previous Close | 1.58 |
| Day's Range | 1.54 - 1.59 |
| 52-Week Range | 1.08 - 2.18 |
| Beta | 1.47 |
About THTX
Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA and EGRIFTA SV, for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo, an injection refers to ibalizumab for the treatment of multidrug resistant ...
Sector Healthcare
IPO Date Feb 13, 2009
Employees 103
Stock Exchange NASDAQ
Ticker Symbol THTX
Website https://www.theratech.com
Next Earnings Release
Theratechnologies Inc. is scheduled to release its earnings on Apr 9, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
3 weeks ago
-12.09%
Theratechnologies shares are trading lower. The co...
Unlock content with
Pro Subscription
1 month ago
+7.36%
Theratechnologies shares are trading higher after the company announced it has resumed the distribution of EGRIFTA.
